A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment
AbstractBackground Hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) is a rare genetic disease. The symptoms can resemble other forms of hereditary angioedema (HAE), but the specific laboratory values are inconspicuous. The knowledge about treatment strategies in HAE-nC1-INH remains insuf...
Main Authors: | Robin Lochbaum, Susanne Trainotti, Thomas K. Hoffmann, Jens Greve, Janina Hahn |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2023.2290362 |
Similar Items
-
Mutant plasminogen in hereditary angioedema is bypassing FXII/kallikrein to generate bradykinin
by: Stefan Hintze, et al.
Published: (2023-01-01) -
Diagnosis and screening of patients with hereditary angioedema in primary care
by: Henao MP, et al.
Published: (2016-05-01) -
Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
by: Andrea Zanichelli, et al.
Published: (2018-10-01) -
The Genetics of Hereditary Angioedema: A Review
by: Rosa Santacroce, et al.
Published: (2021-05-01) -
Angioedema Without Wheals: Challenges in Laboratorial Diagnosis
by: Anete S. Grumach, et al.
Published: (2021-12-01)